Mark Rothera
2015 - PTC Therapeutics
In 2015, Mark Rothera earned a total compensation of $2.8M as Chief Commercial Officer at PTC Therapeutics, a 40% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,172 |
|---|---|
| Option Awards | $2,225,711 |
| Salary | $425,390 |
| Other | $7,873 |
| Total | $2,846,146 |
Rothera received $2.2M in option awards, accounting for 78% of the total pay in 2015.
Rothera also received $187.2K in non-equity incentive plan, $425.4K in salary and $7.9K in other compensation.
Rankings
In 2015, Mark Rothera's compensation ranked 3,356th out of 13,638 executives tracked by ExecPay. In other words, Rothera earned more than 75.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,356 out of 13,638 | 75th |
Division Manufacturing | 1,217 out of 5,187 | 77th |
Major group Chemicals And Allied Products | 443 out of 1,857 | 76th |
Industry group Drugs | 353 out of 1,531 | 77th |
Industry Pharmaceutical Preparations | 280 out of 1,179 | 76th |
Source: SEC filing on April 27, 2017.
Rothera's colleagues
We found four more compensation records of executives who worked with Mark Rothera at PTC Therapeutics in 2015.